People · Operator
Named in public records as an officer, director or promoter · active 2011–2016 · Other Health Care, Biotechnology, Other Technology, Healthtech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vertiflex, Inc. | — | Other Health Care | Series C | $134.1M | $1.0B | 2015 |
| Tendyne Holdings, Inc. | — | Biotechnology | Series B | $67.5M | $992.2M | 2012 |
| Capsilon Corp | — | Other Technology | Series B | $42.3M | $652.8M | 2014 |
| Cianna Medical Inc | — | Healthtech | Series A | $30.5M | $95.9M | 2015 |
| ReCor Medical, Inc. | — | Biotechnology | Series B | $22.0M | $873.2M | 2016 |
| PathCentral, Inc. | — | Other Technology | Series A | $15.9M | $52.9M | 2012 |
| AnaBios Corp | — | Biotechnology | Series A | $14.7M | $94.0M | 2011 |
| Freedom Meditech Inc | — | Other | Series A | $13.2M | $73.8M | 2014 |
| Fresca Medical, Inc. | — | Healthtech | Seed | $7.3M | $50.0M | 2014 |
Martin J. Waters at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin J. Waters on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Feuchter | 1 | 12 |
| Eugene Chen | 1 | 9 |
| George Wallace | 1 | 8 |
| Peter Justin Klein | 1 | 7 |
| Paul Klingenstein | 1 | 6 |
| Timothy B. Petersen | 1 | 5 |
| Peter Klein | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Andrew Cragg | 1 | 5 |
| Paul Miller | 1 | 5 |
| Michael J. Danaher | 1 | 5 |
| Robert Brownell | 1 | 4 |
| Andrew M. Weiss | 1 | 3 |
| Guy P. Nohra | 1 | 3 |
| Joseph M. Smith | 1 | 3 |
| John Cox | 1 | 3 |
| Steven L. Gex | 1 | 3 |
| David E. Anderson | 1 | 3 |
| Matthew Weil | 1 | 3 |
| Dan Bradbury | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.